+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma

RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma

Cancer Biology & Therapy 12(1): 9-46

RON (MST1R) is one of two members of the MET receptor tyrosine kinase family, along with parent receptor MET. RON has a putative role in several cancers, but its expression and function is poorly characterized in gastroesophageal adenocarcinoma. A recognized functional role of MET tyrosine kinase in gastroesophageal cancer has led to early phase clinical trials using MET inhibitors, with unimpressive results. Therefore, the role of RON in gastroesophageal cancer, as well as its role in cooperative signaling with MET and as a mechanism of resistance to MET inhibition, was studied in gastroesophageal tissues and cell lines. By IHC, RON was highly over-expressed in 74% of gastroesophageal samples (n=94), and over-expression was prognostic of poor survival (p=0.008); RON and MET co-expression occurred in 43% of samples and was prognostic of worst survival (p=0.03). High MST1R gene copy number by quantitative polymerase chain reaction, and confirmed by fluorescence in situ hybridization and/or array comparative genomic hybridization, was seen in 35.5% (16/45) of cases. High MST1R gene copy number correlated with poor survival (p=0.01), and was associated with high MET and ERBB2 gene copy number. A novel somatic MST1R juxtamembrane mutation R1018G was found in 11% of samples. RON signaling was functional in cell lines, activating downstream effector STAT3, and resulted in increased viability over controls. RON and MET co-stimulation assays led to enhanced malignant phenotypes over stimulation of either receptor alone. Growth inhibition as evidenced by viability and apoptosis assays was optimal using novel blocking monoclonal antibodies to both RON and MET, versus either alone. SU11274, a classic MET small molecule tyrosine kinase inhibitor, blocked signaling of both receptors, and proved synergistic when combined with STAT3 inhibition (combination index < 1). These preclinical studies define RON as an important novel prognostic marker and therapeutic target for gastroesophageal cancer warranting further investigation.

(PDF same-day service: $19.90)

Accession: 055338210

Download citation: RISBibTeXText

PMID: 21543897

DOI: 10.4161/cbt.12.1.15747

Related references

Interobserver agreement and assay reproducibility of folate receptor α expression in lung adenocarcinoma: a prognostic marker and potential therapeutic target. Archives of Pathology & Laboratory Medicine 137(12): 1747-1752, 2014

Prognostic importance and therapeutic implications of PAK1, a drugable protein kinase, in gastroesophageal junction adenocarcinoma. Plos One 8(11): E80665-E80665, 2014

14-3-3ζ as a prognostic marker and therapeutic target for cancer. Expert Opinion on Therapeutic Targets 14(12): 1343-1354, 2011

Galectin-3, a prognostic marker--and a therapeutic target?. Revista Portuguesa de Cardiologia 34(3): 201-208, 2015

YB-1: oncoprotein, prognostic marker and therapeutic target?. Biochemical Journal 449(1): 11-23, 2013

New tumour antigen PLAC1/CP1, a potentially useful prognostic marker and immunotherapy target for gastric adenocarcinoma. Journal of Clinical Pathology 68(11): 913-916, 2016

SGEF is a potential prognostic and therapeutic target for lung adenocarcinoma. World Journal of Surgical Oncology 16(1): 32-32, 2018

CD38 at the junction between prognostic marker and therapeutic target. Trends in Molecular Medicine 14(5): 210-218, 2008

Aurora B: a new prognostic marker and therapeutic target in cancer. Current Medicinal Chemistry 18(4): 482-496, 2011

17P Examination of EXOSC4 as a new prognostic marker and a novel therapeutic avenue in lung adenocarcinoma. Journal of Thoracic Oncology 11(4 Suppl): S63-S63, 2016

PPM1D is a prognostic marker and therapeutic target in colorectal cancer. Experimental and Therapeutic Medicine 8(2): 430-434, 2014

Inflammation in cardiac amyloidosis: prognostic marker or therapeutic target?. European Journal of Heart Failure, 2017

CDK9 is a prognostic marker and therapeutic target in pancreatic cancer. Tumour Biology 39(2): 1010428317694304-1010428317694304, 2017

CCR9 as a prognostic marker and therapeutic target in hepatocellular carcinoma. Oncology Reports 31(4): 1629-1636, 2014

S100A4 May Be a Good Prognostic Marker and a Therapeutic Target for Colon Cancer. Journal of Oncology 2018: 1828791-1828791, 2018